Study to probe Jardiance effects on kidney disease
RIDGEFIELD, Conn. and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly and Co. yesterday announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes. EMPA-KIDNEY will be independently conducted, analyzed and reported by the Medical
